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Cyclic AMP promotes growth and secretion in human polycys-
tic kidney epithelial cells.
Background. Progressive cyst enlargement, the hallmark of
autosomal-dominant polycystic kidney disease (ADPKD) and
autosomal-recessive (ARPKD) polycystic kidney disease, pre-
cedes the eventual decline of function in these conditions. The
expansion of individual cysts in ADPKD is determined to a
major extent by mural epithelial cell proliferation and transep-
ithelial fluid secretion. This study determined if common
receptor-mediated agonists and an anonymous lipid stimulate
the production of 3′ 5′-cyclic monophosphate (cAMP) in mu-
ral epithelial cells from the two major types of human cystic
diseases.
Methods. cAMP responses to maximally effective concentra-
tions of renal agonists were determined together with measure-
ments of transepithelial anion current and cellular proliferation
and extracellular signal-related kinase (ERK 1/2) expression in
primary cultures of epithelial cells from human ADPKD and
ARPKD cysts.
Results. The rank orders of responses to ligands for
ADPKD and ARPKD cells were identical: epinephrine >
desmopressin (DDAVP) ≈ arginine vasopressin (AVP) >
adenosine > prostaglandin E2 (PGE2) > parathyroid hor-
mone (PTH). cAMP concentrations elevated by epinephrine,
DDAVP, adenosine, and PGE2 were diminished by receptor-
specific inhibitors. Pools of cyst fluid collected individually from
16 of 19 ADPKD kidneys increased, to varying degrees, cAMP
levels in ADPKD and ARPKD cells. PGE2, b-adrenergic and
AVP antagonists partially inhibited cAMP accumulation in re-
sponse to fluids from three kidneys, but a large portion of
the endogenous activity was attributed to yet-to-be identified
bioactive lipid, designated cyst activating factor (CAF). CAF
stimulated cAMP production in ADPKD and ARPKD cells,
activated ERK1/2, and increased cellular proliferation in
ADPKD cells. CAF increased positive short circuit current (ISC)
in polarized ADPKD and T-84 monolayers, indicating stimula-
tion of net anion secretion.
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Conclusion. Endogenous adenylyl cyclase agonists promote
cell proliferation and electrolyte secretion of human ADPKD
and ARPKD cells in vitro. We suggest that increased levels of
cAMP may accelerate cyst growth and overall renal enlarge-
ment in patients with PKD.
The growth of individual cysts in polycystic kidney dis-
ease (PKD) is determined primarily by epithelial cell
proliferation within cyst walls in conjunction with trans-
mural fluid secretion [1]. Evidence based on studies of
cyst epithelial cells in vitro points strongly to a role for
adenosine 3′ 5′-cyclic monophosphate (cAMP) in deter-
mining the rate of cyst epithelial cell growth and fluid se-
cretion [2–7]. Thus, natural receptor-mediated agents that
activate adenylyl cyclase [arginine vasopressin (AVP),
prostaglandin E2 [PGE2], catecholamines, and adeno-
sine] and inhibitors of phosphodiesterase (caffeine and
theophylline) have the potential to accelerate the rate of
renal enlargement in PKD [8, 9]. A novel neutral lipid iso-
lated from cyst fluids, named cyst activating factor (CAF),
can be added to this conventional list of agonists [10, 11].
Recently, Gattone et al [12, 13] found that inhibition
of vasopressin V2 receptor coupling to adenylyl cyclase
was sufficient to dramatically diminish the formation
and growth of renal cysts in animals with three differ-
ent hereditary renal cystic disorders. Renal function was
preserved in all instances. This compelling body of work
places cAMP in a final common pathway in situ for the
regulation of growth in most, if not all, hereditary renal
cystic disorders, opening opportunities for specific treat-
ment with agents that block the activation of adenylyl
cyclase by hormones and autacoids.
The regulation of cell proliferation and fluid secre-
tion by cAMP has been examined in human autosomal-
dominant PKD (ADPKD) but the relative roles of
hormones and autacoids that activate adenylyl cyclase are
incompletely understood. In the current study we used
a standard protocol to evaluate more rigorously the re-
sponses of both human ADPKD and autosomal-recessive
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PKD (ARPKD) cyst epithelial cells to physiologically
important adenylyl cyclase agonists and CAF. The ex-
panded list of agonists under examination and the inclu-
sion of human ARPKD cells are important new features
of this study. We also sought to determine if cyst fluids
harbor any of these agonists, thereby providing a poten-
tial reservoir for sustained activation of adenylyl cyclase.
The results indicate that receptor-mediated agonists and
an anonymous lipid derived from human ADPKD cysts
have the capacity to stimulate cAMP production in both
human ADPKD and ARPKD cells in vitro.
METHODS
Cultures of human ADPKD and ARPKD cells
Mural cells were retrieved from renal cysts of two adult
patients with ADPKD and two infants with ARPKD who
underwent elective nephrectomy as part of their treat-
ment plan. The diagnosis was verified by anatomic exam-
ination. Explicit genotypic data were not available. The
discarded but viable kidneys were packed immediately in
ice (4◦C) and shipped by expedited delivery to the labo-
ratory. Cells removed from cortical cysts were placed in
primary culture as described previously [14, 15]. Primary
cultures were used for immediate studies or frozen in
10% dimethyl sulfoxide (DMSO) for future use. ADPKD
cells retained the capacity to form a differentiated epithe-
lium for at least three passages; by contrast, ARPKD cells
could be used for more than ten passages. The protocol
was approved by the Institutional Review Board at the
University of Kansas Medical Center.
Cells maintained in liquid nitrogen were thawed and
grown in plastic flasks containing a 1:1 mixture of Dul-
becco’s modified Eagle’s medium (DMEM) and Ham’s
F12 (DMEM/F12) supplemented with 5% fetal bovine
serum (FBS) (Hyclone, Logan, UT, USA), 100 U/mL
penicillin, 0.1 mg/mL streptomycin, and 5 lg/mL in-
sulin, 5 lg/mL transferrin, and 5 ng/mL sodium selen-
ite (ITS) (Collaborative Biomedical Products, Bedford,
MA, USA). Then cells were seeded onto 24-well plates
(Costar, Cambridge, MA, USA). Media were replaced
every 2 days.
Cyst fluid
Fluids were collected, as described previously [16, 17],
from the cysts of 19 individuals with advanced ADPKD.
The kidneys were handled as noted above and shipped by
expedited delivery to the laboratory. Surface cysts con-
taining clear liquid were aspirated, and the fluids removed
from a single kidney or a pair were mixed together to form
a single large pool. Sediment was removed by centrifuga-
tion and the supernatant was stored at –20◦C.
Measurements of intracellular cAMP
Two × 105 cells were seeded into individual chambers
(1.9 cm2) of 24-well plates in DMEM/F12 containing 5%
FBS, ITS, and penicillin/streptomycin. Near confluence,
the medium was changed to 1% FBS to reduce the rate of
basal growth. Twenty-four hours later, cells were rinsed
in fresh DMEM/F12 containing 1% FBS for 15 minutes.
The rinsing procedure ensured the removal of autocrine
cAMP agonists that may have accumulated in the condi-
tioned medium. Stock solutions (1:100 to 1:1000 dilutions
into buffered saline) of desmopressin (DDAVP), AVP,
PGE2, epinephrine, and adenosine were added directly
to the incubation medium. Each sample was determined
in quadruplicate and statistically significant stimulation
above baseline (P < 0.05) was determined by unpaired
t test.
Stock solutions of the following were added to
medium: AVP-V2R antagonist (b-mercapto-b , b-
cyclopentamethylene propion-O-methyl-Tyr2, Arg8),
vasopressin, indomethacin, and a b 2 adrenergic receptor
inhibitor (ICI-118551). An EP4 PGE2 receptor antago-
nist (L-161982) was dissolved in DMSO. Forskolin and a
b 1 inhibitor (atenolol) were dissolved in ethanol. Equiva-
lent concentrations of water or other carriers were added
to control media. AVP, PGE2, epinephrine, adenosine,
atenolol and forskolin were purchased from Sigma
(St. Louis, MO, USA). DDAVP was purchased from
Rhone Poulenc Rorer Pharmaceuticals (Collegeville, PA,
USA). ICI-118551 was purchased from Biomol (Butler
Pike, PA, USA). L-161982 was a gift of Merck-Frosst
Canada and Co. (Kirkland, Quebec, Canada).
The cells were harvested for cAMP determinations
15 minutes after adding the respective agonists. Inhibitors
were added at least 30 minutes before the agonists. Intra-
cellular cAMP was extracted from epithelial cells in the
individual wells (area 1.9 cm2) into 80% methanol, recon-
stituted in 0.05 mol/L sodium acetate and quantified by
an enzyme immunoassay system (Amersham Pharmacia
Biotech, Buckinghamshire, UK) as described previously
[9].
Bioelectric measurements
Polarized, confluent monolayers of T-84 and ADPKD
cells, grown on permeable supports (Snapwell 1.1 cm2
area) (Costar), were mounted in modified Ussing cham-
bers as described previously [14, 15, 18]. The device
contained 4 mL of media in each of two chamber halves
separated by the monolayer and the media were gassed
and stirred with a low stream of 5% CO2/95% O2.
Medium was an isotonic Ringer’s solution that con-
tained no serum or serum components maintained at
37◦C. CAF samples stored in chloroform:methanol (1:1)
were dried under liquid nitrogen and dissolved in 100 lL
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DMEM/F12 + 0.1% decomplimented FBS. The transep-
ithelial potential difference (Vte), short-circuit current
(Isc), and transepithelial resistance (Rte) were deter-
mined as described previously [15, 18]. The monolay-
ers were maintained in the short-circuited state, and the
open-circuit voltage was determined at 1- to 5-minute
intervals. After a period of equilibration, sequential
Isc measurements were recorded. Steady-state Isc was
recorded, typically 15 to 20 minutes after the addition of
agonists or CAF extracts to the basolateral medium.
Immunoblot analysis
Methods identical to those reported recently were
used [4, 5]. Cells (105) were seeded onto 100 mm di-
ameter plastic dishes in DMEM/F12 with 5% FBS, ITS,
and penicillin/streptomycin. As the cells approached con-
fluency, FBS was reduced to 1% for 24 hours. Prior
to incubation with agonists, cells were washed in 1%
FBS for 15 minutes. Forskolin, DDAVP, or extracts of
CAF were added for 15 minutes. Cells were lysed in
500 lL of ice-cold buffer (TLB) [20 mmol/L Tris (pH
7.4), 137 mmol/L NaCl, 25 mmol/L b-glycerophosphate,
2 mmol/L ethylenediaminetetraacetic acid (EDTA), 1
mmol/L sodium orthovanadate, 2 mmol/L NaHPO4, 1%.
Triton X-100, 10% glycerol, 1 mmol/L phenylmethylsul-
fonyl fluoride (PMSF), 5 lg/mL aprotinin, 5 lg/mL leu-
peptin, 2 mmol/L benzamidine, and 0.5 mmol/L dithio-
threitol (DTT)]. Cell lysates were centrifuged to obtain
soluble fractions, aliquots of which were quantified for
protein. Aliquots (20 lg protein) were then heated (95 to
100◦C) in sodium dodecyl sulfate (SDS) sample buffer,
separated by 10% SDS-polyacrylamide gel electrophore-
sis (PAGE), and transferred to nitrocellulose membranes
(Hybond ECL) (Amersham, Buckinghamshire, UK). Af-
ter transfer, the membranes were blocked with 5% milk
in TBS-T (20 mmol/L Tris-HCl, 137 mmol/L NaCl, and
0.05% Tween 20, pH 8.0) for 1 hour at room temperature
and then incubated with primary antibody in 5% milk
in TBS-T for 2 hours at room temperature or overnight
at 4◦C. Membranes were next washed (3×) with TBS-T
and incubated with secondary antibody with 5% milk in
TBS-T for 1 hour and finally were washed (3×) with TBS-
T. Proteins were visualized using an enhanced chemilu-
minescence system (ECL) (Amersham Life Science, Ar-
lington Heights, IL, USA). Resolved protein bands were
detected and quantified by a Fluor-S Max multi-imager
system (Bio-Rad, Hercules, CA, USA).
Antibodies specific for ERK1 (C-14), ERK2 (C-16),
and phospho-ERK (E-4) were purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). Secondary
antibodies were derived from antirabbit, antimouse, or
antirat IgG-conjugated horseradish peroxidase (HRP)
(Santa Cruz Biotechnology).
Cell proliferation
The Promega Cell Titer 96 MTT assay method (Madi-
son, WI, USA) was used to determine the relative rates of
cell proliferation under different experimental conditions
[19]. This method, which measures the optical density of
a proliferation-dependent reaction product, was found
to correlate directly with determinations of cell num-
ber using a direct cell-counting technique. To determine
the effects of agonists on the rate of proliferation, ap-
proximately 4000 cells were seeded into individual cham-
bers of a 96-well plate. The cells were incubated initially
in DMEM/F12 medium supplemented only with peni-
cillin, streptomycin, ITS, and 1% FBS. After 24 hours,
the FBS was reduced to 0.002% (ITS-deleted) to arrest
growth. Specific agonists were added for another 48 to
72 hours. Preliminary studies were examined for desqua-
mated cells, and no consistent effects of agonists were
detected on the number of cells in the supernatant. In-
hibitors of protein kinase A activity, H-89 and Rp cAMP,
were added for 30 minutes before the agonists.
CAF extraction and separation
We employed a two-phase system with two washes to
extract 10 to 50 mL samples of human cyst fluid [20].
Following published procedures, crude lipids were sep-
arated by thin-layer chromatography on plates of silica
gel (K6) (60 A

particle size, 250 lm thickness) (What-
man, Clinton, NJ, USA), with development in chloro-
form/acetone/methanol/acetic acid/water (5:2:1:1:0.5, by
volume) [21]. Lipids were recovered from bands 0.5 to
1.0 cm in width and labeled 1 to 10. In this system polar
lipids generally exhibit Rf values <0.5 and neutral com-
pounds Rf values >0.7. Reference lipids were included at
the edges and marked after brief development in iodide
vapor.
Active fractions, determined by cAMP or Isc assays in
ADPKD and T-84 cell monolayers, were then subjected
to normal-phase, isocratic high-performance liquid chro-
matography (HPLC) [22]. The instrumentation was an
LC-6A system (Shimadzu, Columbia, MD, USA) con-
trolled by Class-VP software, columns were lPorasil, 3.9
× 300 mm (Waters, Milford, MA, USA), and the elution
solvent was hexane/2-propanol/acetic acid (100:10:0.02,
by volume). Column fractions were monitored at 206
nm, but CAF levels were too low to be detected by ul-
traviolet or light spectroscopy. An inactive neutral lipid,
2-oleoylglycerol, was employed as an internal standard.
Crude and purified lipid fractions were taken to dryness
in vacuo, reconstituted in chloroform/methanol (1:1, by
volume), and stored at −20◦C under N2.
Lipid standards, including free fatty acids, 1-
acylglycerol, 1,2-diacylglycerol, several glycerophospho-
lipids, sphingosine, ceramide, and several eicosanoids,
were obtained from Avanti Polar Lipids (Alabaster, AL,
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USA), Cayman Chemical (Ann Arbor, MI, USA), and
Sigma-Aldrich (St. Louis, MO, USA). HPLC grade sol-
vents and other chemicals were purchased from Fisher
(Pittsburgh, PA, USA).
RESULTS
cAMP agonist effects on ADPKD and ARPKD cells
Recent studies demonstrated that inhibition of AVP
V2 receptor blockade of adenylyl cyclase activation strik-
ingly reduced the enlargement of renal cysts in three
strains of rodents with hereditary cystic disorders. These
findings have important therapeutic implications; how-
ever, before direct application to humans it is important
to confirm that cAMP has a central role in the target cells
derived from human renal cysts.
In the current in vitro study, we determined the relative
capacities of several agonists to increase cAMP in mural
epithelial cells derived from the cysts of patients with two
major types of hereditary polycystic disease, ADPKD
and ARPKD. ARPKD cells were used for preliminary
screening studies since the yield from primary cultures
was greater than for ADPKD cells. The effects of key ag-
onists were then directly compared between the ADPKD
and ARPKD genotypes.
Highly specific inhibitors were used to confirm that in-
creases in cAMP caused by the different ligands were
receptor-mediated. We also searched for anonymous
cAMP agonists by adding to ADPKD and ARPKD cells
cyst fluids collected from ADPKD patients. Receptor
blockers were used to determine if common adenylyl cy-
clase agonists accounted for increases in cAMP caused
by cyst fluid.
The cAMP responses of ADPKD and ARPKD cells
to maximally effective concentrations of the respective
agonists were compared (Table 1). Concentrations suf-
ficient to maximally increase cellular cAMP were deter-
mined in preliminary studies (data not shown). Forskolin
(10 lmol/L), which directly activates adenylyl cyclase to a
maximal extent, was used as a positive control. The effect
of each agonist to raise cell cAMP above baseline levels
was determined as a percent of the maximal forskolin re-
sponse in cells from the same preparation. In this calcu-
lation, given in the legend to Table 1, the baseline level of
cAMP is subtracted from the response to experimental
agonist and to forskolin. The calculated change, there-
fore, reflects the percent elevation of cAMP above the
baseline in relation to a maximal response to forskolin.
In Table 1 forskolin increased cAMP in ADPKD from
baseline of 1.4 to 26.8 ± 3.2 pmol/sample (N = 4); in
ARPKD forskolin increased cAMP from baseline 1.3 to
34.3 ± 6.6 pmol/sample (N = 12). In Figure 1, forskolin
increased cAMP in four preparations derived from an
ARPKD kidney from baseline of 0.7 ± 0.2 pmol/sample
to 21.5 ± 2.0 pmol/sample, N = 4. In Figure 2, forskolin
Table 1. Effect of receptor-mediated agonists and antagonists on 3′ 5′
cyclic monophosphate (cAMP) production by autosomeal-dominant
polycystic kidney disease (ADPKD) and autosomal-recessive
polycystic kidney disease (ARPKD) cells
cAMP level (relative to forskolin)%a
ADPKD cells ARPKD cells
Epinephrine (1 lmol/L) 95.8 ± 4.4b (4) 94.7 ± 3.0b (4)
Epinephrine (1 lmol/L) +
atenolol (10 lmol/L) +
ICI-118551 (10 lmol/L)
0.5 ± 0.1 (4) 0.0 ± 0.0 (4)
DDAVP (100 mU/mL) 64.7 ± 2.6b (12) 86.6 ± 0.9b,c (12)
DDAVP + AVP V2 receptor
antagonist (1 lmol/L)
0.0 ± 0.0 (4) 2.2 ± 0.6 (4)
AVP (100 mU/mL) 54.8 ± 3.2b (12) 81.6 ± 4.4b,c (4)
Adenosine (100 lmol/L) 63.1 ± 7.0b (8) 71.2 ± 2.3b (4)
Dimethyl-propargyl (10
lmol/L) + adenosine
24.5 ± 2.9 (4) 39.7 ± 1.3 (4)
PGE2 (0.4 lmol/L) 45.7 ± 1.8d (7) 51.4 ± 15.7b (8)
L-161982 (1lmol/L) + PGE2 20.3 ± 4.1 (3) 5.3 ± 0.2 (4)
Parathyroid hormone (10
nmol/L)
20.6 ± 1.1d (4) 5.7 ± 0.4c,d (4)
Abbreviations are: DDAVP, desmopressin; AVP, arginine vasopressin; PGE2,
prostaglandin E2.
aExperimental − baseline/(forskolin − baseline) × 100. Mean forskolin
response, ADPKD 26.8 ± 3.2 pmol/sample (N = 4); ARPKD 34.3 ± 6.6
pmol/sample (N = 12). Baseline, ADPKD 1.4 pmol/sample; ARPKD 1.3
pmol/sample. Results are expressed as the mean ± SE for the indicated number
of measurements.
bP < 0.001, differences from baseline levels by analysis of variance (ANOVA).
cP < 0.001, difference between ADPKD and ARPKD cells by unpaired t test.
dP < 0.01, differences from baseline levels by ANOVA.
increased cAMP levels in 11 ARPKD preparations from
baseline of 0.7 ± 0.2 pmol to 19.6 ± 3.2 pmol and nine
ADPKD preparations from baseline of 0.7 ± 0.1 pmol to
12.0 ± 1.3 pmol.
Surprisingly, epinephrine was the most potent
receptor-mediated agonist tested in both ADPKD and
ARPKD cells (Table 1). The effect of epinephrine to raise
cAMP levels was completely inhibited by a combination
of b 1 (atenolol) and b 2 (ICI-118551) adrenergic receptor
blockers.
AVP and the V2-specific agonist, DDAVP, raised
cAMP levels in ARPKD cells to a greater extent than
in ADPKD cells (Table 1). The difference in the de-
gree of stimulation is probably related to the fact that
ARPKD cells were derived primarily from cortical col-
lecting ducts, whereas ADPKD cells represent a broader
mixture of progenitor cells from the cortex, including
proximal tubule, distal tubule, and collecting ducts [5, 23].
A specific AVP V2 receptor antagonist (1 lmol/L) virtu-
ally eliminated the elevation of cAMP caused by DDAVP
in both ADPKD and ARPKD cells. The observation that
the cAMP responses to DDAVP and AVP were nearly
identical within each cell line suggests that the V1 recep-
tor did not alter cAMP production or metabolism to a
detectable extent.
PGE2 (0.4 lmol/L) stimulated the accumulation of
cAMP in ADPKD and ARPKD cells to about the same
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Fig. 1. Concentration-dependent effects of 12 pools of autosomal-
dominant polycystic kidney diseae (ADPKD) cyst fluid on 3′ 5′ cyclic
adenosine monophosphate (cAMP) levels in autosomal-recessive poly-
cystic kidney disease (ARPKD) cells. Boxed symbols indicate cyst fluids
from individual patients. Cyst fluids were diluted in medium and added
for 15 minutes. cAMP expressed in relation to the maximal forskolin
response in each experiment. Eleven of 12 cyst fluids showed significant
stimulation above baseline (P < 0.05) for 1%, 5%, and 10% concen-
trations when evaluated by unpaired t test. Forskolin increased cAMP
in four preparations derived from an ARPKD kidney from baseline of
0.7 ± 0.2 pmol/sample to 21.5 ± 2.0 pmol/sample (N = 4).
degree (Table 1). The EP4 specific antagonist, L-161982
(1 lmol/L), reduced the effect of PGE2 to a greater
degree in ARPKD than in ADPKD cells. Adenosine
potently stimulated cAMP levels in both ADPKD and
ARPKD cells (Table 1). This effect was partially inhib-
ited by an adenosine A2 receptor antagonist.
Parathyroid hormone (PTH) increased cAMP in
ADPKD to a greater level than in ARPKD cells
(Table 1). This is opposite to the effect of AVP noted
above, but like vasopressin, is probably a reflection of
the fact that the ADPKD preparations are comprised
of a higher proportion of proximal tubule segments than
ARPKD preparations. A PTH receptor inhibitor was not
available.
These results establish that both ADPKD and ARPKD
cells responded to cAMP agonists in the same order:
epinephrine > DDAVP ≈ AVP > adenosine > PGE2 >
PTH.
Evaluation of unfractionated cyst fluid agonists
To determine if cysts harbored potential adenylyl cy-
clase agonists, we determined the capacity of fluids re-
trieved from human cysts to elevate cAMP in ARPKD
cells. Cyst fluids were diluted with DMEM/F12 to work-
ing concentrations of 1%, 5%, and 10%. The increase
in cell cAMP content stimulated by cyst fluid was
concentration-dependent (Fig. 1). Concentrations higher
than 10% were not tested in order to minimize the poten-
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Fig. 2. Capacity of autosomal-dominant polycystic kidney disease
(ADPKD) cyst fluid to stimulate 3′ 5′ cyclic adenosine monophosphate
(cAMP) accumulation in ADPKD and autosomal-recessive polycystic
kidney disease (ARPKD) cells in vitro. A 10% concentration of fluid
from each of 19 ADPKD cysts was added for 15 minutes to 19 mono-
layers of ARPKD cells () and 13 monolayers of ADPKD cells ( )
(N = 4 each). cAMP (% of maximal forskolin response) was increased
in the ARPKD cells by all but three cyst fluids determined by nonpaired
t test. The inset shows the linear correlation between responses to cyst
fluid in ARPKD in comparison to ADPKD cells. cAMPADPKD = 0.38
+ 0.907 cAMPARPKD, r2 = 0.921. Forskolin increased cAMP levels in
11 ARPKD preparations from baseline of 0.7 ± 0.2 pmol to 19.6 ± 3.2
pmol and 9 ADPKD preparations from baseline of 0.7 ± 0.1 pmol to
12.0 ± 1.3 pmol.
tial effects of uremic toxins that may have accumulated
in the azotemic patients.
In subsequent studies, a 10% concentration was used to
determine the relative cAMP responses of ARPKD and
ADPKD cells to individual pools of cyst fluid. Sixteen of
19 cyst fluids selected for this study stimulated cAMP lev-
els above the baseline in ARPKD cells (P < 0.05) (Fig. 2).
Thirteen of these fluids were added to ADPKD cells, and
11 of them increased cAMP accumulation to about the
same extent as they did in ARPKD cells (Fig. 2). The re-
lation between the cAMP content of ADPKD in compar-
ison to ARPKD cells was linear ([cAMP]ADPKD = 0.38 +
0.907 × [cAMP]ARPKD, r2 = 0.921). Taken together, this
set of experiments shows that agonists in ADPKD cyst
fluid have the capacity to stimulate cAMP accumulation
in both ADPKD and ARPKD epithelial cells.
To reveal the identities of the putative agonists, nine
cyst fluids with the highest capacities for stimulating
cAMP accumulation were added to PKD cells together
with specific b-adrenergic, AVP-V2, or PGE2 receptor
blockers, or with indomethacin, which inhibits eicosanoid
synthesis. An effect of an antagonist to significantly di-
minish the increase in cAMP caused by the cyst fluid was
taken to indicate the presence of the ligand in the cyst
fluid. b-adrenergic, AVP-V2, and PGE2 receptor block-
ers diminished the cAMP response of ADPKD cells to
cyst fluid; however, only three fluids appeared to contain
significant quantities of the agonists (Table 1) (Fig. 3).
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Fig. 3. 3′ 5′ cyclic adenosine monophosphate (cAMP) agonists de-
tected in autosomal-dominant polycystic kidney disease (ADPKD) cyst
fluids (CF). Nine cyst fluid pools were screened and three were found to
contain appreciable quantities of common cAMP agonists. L-161982, an
EP4 receptor antagonist, reduced the effect of prostaglandin E2 (PGE2)
on cAMP cells by 52%. The inhibitor reduced the capacities of CF 1 and
CF 2 to increase cAMP levels by 25% and 47%, respectively. Atenolol
and ICI-118551, agents that block b1 and b2 adrenergic receptors, re-
spectively, completely inhibited the effect of epinephrine. The b block-
ers reduced the cAMP levels elevated by CF 2 and CF 3 by 38% and
57%, respectively. The arginine vasopressin (AVP) V2 receptor antag-
onist completely inhibited the effect of desmopressin (DDAVP). This
inhibitor reduced by 67% the capacity of CF 3 to elevate cAMP.
The adenosine A2 antagonist evaluated in Table 1 had
no effect on cAMP accumulation caused by cyst fluids
with high intrinsic activity, and this was confirmed by di-
rect measurements of adenosine with a sensitive HPLC
method (data not shown). Thus, a large component of the
agonist activity in the high capacity fluids of Figure 2 was
unaccounted for.
Evaluation of partially purified cyst fluid lipids
We had previously shown that fluids from certain cysts
contained a relatively potent neutral lipid that stimulated
cAMP production in renal epithelial cells [10, 11]. The
cyst fluids examined in this study were screened for the
presence of CAF by determining the capacity of a chloro-
form:methanol (1:1) extract to increase Isc in monolayers
of T-84 cells grown on permeable supports (Fig. 4A). T-84,
an immortal cell line derived from a human colon ade-
nocarcinoma laden with a high density of cystic fibrosis
transmembrane conductance regulator (CFTR) chloride
channels within apical membranes, has been used exten-
sively to study receptor-mediated transepithelial chloride
secretion mediated by cAMP [24]. CAF extracts, recon-
stituted in medium and applied to these cells, caused a
sharp rise in positive Isc (Fig. 4A), indicative of an in-
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Fig. 4. Effect of cyst activating factor (CAF) in cyst fluid 2 on short-
circuit current (Isc) in T-84 cells. (A) Time course of Isc after adding
(arrow) a chloroform:methanol (1:1) extract of cyst fluid (CF 2) in Dul-
becco’s modified Eagle’s medium (DMEM)/F12 solvent. (B) Thin-layer
chromatography (TLC), CF 2 CAF activity was confined to fraction
8, between monoacylglycerol (MAG) and diacylglycerol (DAG). In-
set, Time course of active fraction 8 and inactive fraction 5. (C) High-
performance liquid chromatography (HPLC), CF 2 CAF activity was
confined to the 2- to 6-minute collections. MAG indicated by arrow.
Inset, Time course of the 4-to 6-minute and 8-to 10-minute fractions.
In this series of studies, forskolin alone increased Isc from a baseline of
1.5 ± 0.3 lAmp/cm2 to 52.9 ± 3.1 lAmp/cm2 (N = 4).
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Fig. 5. Effect of cyst activating factor (CAF) on 3′ 5′ cyclic adeno-
sine monophosphate (cAMP) accumulation in autosomal-dominant
polycystic kidney disease (ADPKD) cells. Thin-layer chromatography
(TLC)- and high-performance liquid chromatography (HPLC)-purified
CAF fractions were pooled from cyst fluids (CF) 1, 3, 6, and 8. CAF addi-
tion approximated the active lipid in a ∼25% concentration of the origi-
nal cyst fluid. Indomethacin (10 lmol/L), L-161982 (1 lmol/L), atenolol
(10 lmol/L) + ICI – 118551 (10 lmol/L) were added 30 minutes before
CAF. Values are means ± SE (N = 3). None of the inhibitors had an ef-
fect. Forskolin (10 lmol/L) increased cAMP to 13.4 ± 0.03 pmol/sample
(N = 3).
crease in net chloride secretion. Relatively high levels of
CAF activity were found in cyst fluids 1 to 6; activity was
detected in fluids 7 to 16; and activity was undetectable
in fluids 17 to 19 (see Fig. 2).
CAF was further purified by thin-layer chromatogra-
phy (TLC) into a discreet band that migrated between
mono-and diacylglycerols (Fig. 4B) [10, 11]. Crude chlo-
roform/methanol extracts of cyst fluids with high capac-
ities to stimulate Isc in T-84 cells also had high levels of
CAF in specific TLC band 8 (Fig. 4B, inset). By contrast,
the other TLC fractions were relatively inactive. CAF
in the high activity TLC band was further separated by
normal-phase HPLC into a relatively narrow region of
high activity (Fig. 4C and inset). This activity did not co-
elute with PGE2 or arachidonic acid, other lipids known
to activate adenylyl cyclase.
Because cyst fluids 1, 3, 6, and 8 shared identical TLC
and HPLC characteristics (data not shown), aliquots of
these extracts were pooled in order to have an adequate
supply of highly active common source material for the
remainder of the experiments. In each experiment a con-
stant amount of CAF was applied approximating the
amount of active lipid in a 25% solution of the original
cyst fluid.
CAF stimulated cAMP accumulation in ADPKD cells
(Fig. 5). Indomethacin pretreatment of the cells did not
alter the subsequent effect of CAF to increase the cAMP
content, demonstrating that the effect of CAF is not me-
diated through the generation of an eicosanoid. An EP4
PGE2 receptor blocker had no effect on CAF in either
ARPKD or ADPKD cells. Blockade of b-adrenergic re-
ceptors also had no effect on the response of cells to CAF.
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Fig. 6. Effect of cyst activating fluid (CAF), 8-Br-3′ 5′ cyclic adenosine
monophosphate (cAMP) and prostaglandin E2 (PGE2) in autosomal-
dominant polycystic kidney disease (ADPKD). Short-circuit current
(Isc) determined in monolayers of ADPKD on permeable supports.
Values are means ± SE (N = 3) of steady-state Isc after 15 to 20 minutes.
Additions were CAF (∼25% concentration of original cyst fluid), PGE2
(0.4 lmol/L), and 8-Br cAMP (100 lmol/L). ∗P for all values vs. baseline
< 0.001.
Thus, CAF appears to be an uncommon, if not unique,
bioactive lipid.
Three confluent ADPKD monolayers grown on per-
meable supports developed stable baseline Vte (−0.7 ±
0.07 mV), Rte (282 ± 26 ohm/cm2), and Isc (2.4 ±
0.4 lA

/cm2). CAF added to the basolateral medium sig-
nificantly stimulated Isc (Fig. 6). PGE2 and an analogue
of cAMP, 8-Br-cAMP, also increased steady-state Isc sig-
nificantly in the same preparation of ADPKD cells.
In ADPKD cells, cAMP activates the mitogen-
activated protein (MAP) kinase pathway and comple-
ments the action of epidermal growth factor (EGF) [4, 5]
to stimulate cell proliferation. In the current study, CAF
increased phospho-ERK levels 11-fold above the base-
line (Fig. 7). Phospho-ERK levels were also increased by
PGE2, forskolin, and 8-Br-cAMP.
Although CAF was extracted from ADPKD cyst fluids,
it also stimulated the accumulation of cAMP in ARPKD
cells (71.9 ± 5.6% maximal forskolin response, N =
4). CAF also activated P-ERK in these cells (data not
shown).
In previous studies the activation of ERK in ADPKD
cells was linked to the increased rate of proliferation
caused by the activation of B-Raf by cAMP [4, 5]. CAF,
which elevated cAMP, also stimulated the proliferation
of ADPKD cells to the same extent as EGF (Fig. 8). H-89
and Rp cAMP, two inhibitors that inhibit protein kinase A
(PKA), eliminated the effect of CAF on proliferation as
did PD98059, an inhibitor of MAP kinase kinase (MEK).
Although MEK inhibition completely blocked the effect
of EGF, inhibition of PKA had no effect on the cytokine.
Taken together, these results suggest that the effect of
CAF on the proliferation of ADPKD and ARPKD cells
is probably mediated through the action of cAMP to ac-
tivate B-Raf, and in turn to stimulate the MAP kinase
pathway.
DISCUSSION
Kidney enlargement, often to grotesque proportions,
is the hallmark of most hereditary polycystic disorders
Belibi et al: cAMP and cyst growth 971
0
5
10
15
20
25
P-
ER
K 
fo
ld
 in
du
ct
io
n
P-P44 ERK
P-P42 ERK
 ERK
ADPKD
CAF
PGE2
8-Br cAMP
Forskolin
−
−
−
−
−
−
−
+
−
−
−
+
−
−
−
+
+ − − −
* *
*
*
Fig. 7. Effect of cyst activating factor (CAF) on phospho-extracellular-
related protein kinase (ERK) expression in autosomal-dominant poly-
cystic kidney disease (ADPKD) cells. CAF and other agonists were
added for 15 minutes. Additions were CAF (∼25% concentration of
original cyst fluid), prostaglandin E2 (PGE2) (0.4 lmol/L), 8-Br-3′ 5′
cyclic adenosine monophosphate (cAMP) (100 lmol/L) and forskolin
(10 lmol/L). Upper two rows of a representative immunoblot show
phospho-ERK1 and -ERK2 above two rows from a parallel study show-
ing total ERK1 and ERK2 abundance. Fold increases of phospho-ERK
vs. control determined in three separate experiments shown below the
immunoblots. Values are means ± SE. ∗P < 0.001 vs. baseline.
[25, 26]. The basis for this enlargement lies in the dilation
of individual renal tubules to diameters that may reach
1000 times greater than normal. In the ADPKD, renal en-
largement proceeds progressively over several decades,
culminating in renal failure in approximately one half of
cases. By contrast, in ARPKD, the enlargement is usu-
ally much more rapid, often leading to profound renal
enlargement and failure in the neonatal period.
Abnormal proliferation of renal tubule epithelial cells
underlies the renal enlargement in both ADPKD and
ARPKD [27, 28]. Consequently, polycystic renal disor-
ders are now regarded as benign neoplastic conditions
[29]. Like other growth disorders, the rate of cellular pro-
liferation may be controlled by genetic and environmen-
tal factors. cAMP has been identified as perhaps one of
the most important regulators of cyst growth [4, 6, 7]. The
nucleotide stimulates both the proliferation of cyst mural
cells and the transepithelial secretion of chloride and wa-
ter [2, 3]. Thus, cAMP accelerates two biologic processes
that are of fundamental importance in the expansion of
renal cysts.
In the current study we demonstrated that mural ep-
ithelial cells representing the two major genotypes of
PKD generated increased amounts of cAMP in response
to epinephrine, AVP, adenosine, PGE2, and PTH, ago-
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Fig. 8. Effect of cyst activating factor (CAF) on proliferation of
autosomal-dominant polycystic kidney disease (ADPKD) cells. Ad-
ditions were CAF (∼25% concentration of original cyst fluid), epi-
dermal growth factor (EGF) (25 ng/mL), H-89 (10 lmol/L), Rp 3′ 5′
cyclic adenosine monophosphate (cAMP) (250 lmol/L), and PD98059
(50 lmol/L). Values are means ± SE (N = 12). Forskolin (10 lmol/L)
increased ADPKD cell count 1.56 ± 0.10-fold above baseline. #P < 0.01
vs. CAF; ∗P < 0.001 vs. baseline.
nists known to have important physiologic and patho-
physiologic roles in the regulation of renal function
(Table 1) (Figs. 1 and 2). cAMP is generated normally
within renal tubule cells in response to one or more of
these agonists day and night. The locus of stimulation
might vary within the kidney depending upon hydration
status. Extremes of adenylyl cyclase activation would be
anticipated in antidiuretic states created by water restric-
tion (increased AVP and PGE2 production) or extracel-
lular volume contraction (increased AVP, epinephrine,
PGE2, and adenosine production). Consequently, the
rate of cell proliferation and fluid secretion by cyst epithe-
lial cells could be increased by exposure to agonists ar-
riving in the blood or generated locally as a consequence
of normal homeostatic regulatory events.
The current study demonstrates that cyst epithelial
cells from two genetically different kinds of PKD bear
receptors for conventional hormones and autacoids that
increase cAMP levels in a similar pattern in each type
of cell. It is important to note, however, that the relative
strengths of stimulation noted in these cultured cells may
not hold forth in situ. For instance, we did not determine
the relative effects of the agonists from the apical versus
the basolateral locus of application nor were we able to
control for the possible influence that acquired cystic dis-
ease forces might have had on these cells prior to their
removal from the azotemic patient.
The current data seem consistent with the view that
cells derived from cysts of the cortical collecting ducts
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are the primary locus of the cAMP effects. Lectin bind-
ing studies revealed that most of the cells in ADPKD
and ARPKD cortex cultures originate from collecting
ducts [5, 30–32]. In the current study, ARPKD prepa-
rations had higher cAMP responses to AVP and DDAVP
than ADPKD cells; conversely, ADPKD preparations
had higher responses to PTH than ARPKD cells. In light
of the well-known tubular actions of AVP and PTH these
findings are consistent with a predominance of cysts de-
rived from collecting ducts in both types of PKD, with the
ARPKD preparation containing a slightly higher propor-
tion of collecting duct cysts than ADPKD. This distribu-
tion of cysts is in accord with in situ histochemical studies
of lectin binding in ADPKD and ARPKD [33, 34].
It is conceivable that certain cAMP agonists might
be synthesized and/or secreted by the cyst epithelia and
retained within cysts, thereby creating a reservoir of
adenylyl cyclase stimulants. In the current study highly
specific receptor blockers identified putative effects of
PGE2, adrenergic agonists, and AVP in three pooled cyst
fluids with the highest capacities to stimulate cAMP ac-
cumulation (Fig. 3). Although these common agonists
may accumulate within cysts under the conditions of the
current study, other compounds appeared to account for
a substantial portion of the agonist effects of cyst fluid
on cAMP accumulation within PKD cells (Figs. 1 to 3).
One of these compounds is a neutral lipid (CAF). At
first glance, the potential impact of CAF might be under-
appreciated since the samples of raw cyst fluid added to
the cells were only one tenth as concentrated as that of the
original cyst fluid (Figs. 1 and 2). Extraction and purifica-
tion of CAF permitted the application of larger quantities
of the active material that increased cellular cAMP in T-
84. ADPKD cells to levels approaching that of forskolin
(Figs. 4 to 6). Similar to AVP, PGE2, epinephrine, adeno-
sine, and PTH (Table 1), CAF increased cAMP levels in
ARPKD and ADPKD cells.
CAF strikingly increased Isc in polarized monolayers
of ADPKD epithelial cells, consistent with the stimula-
tion of chloride secretion (Fig. 6) and activated ERK1/2
in both ADPKD (Fig. 7) and ARPKD cells (data not
shown). Accordingly, it appears that the increase in
cAMP caused by CAF activated the MAP kinase pathway
as reported previously for common receptor-mediated
agonists [4, 5]. The activation of ERK 1/2 by CAF ap-
peared to be linked to an increase in cellular proliferation
since the effect could be specifically blocked by inhibitors
of PKA and MEK (Fig. 8). Thus, CAF, like the other
cAMP agonists examined in this study, has the capacity
to stimulate both cellular proliferation and electrolyte se-
cretion and thereby accentuate the enlargement of renal
cysts to a greater extent than agents that act only on one
of these important determinants of cyst enlargement.
The chemical identity of CAF remains an enigma. In-
hibitors of PGE2 did not interfere with the stimulation of
cAMP by CAF excluding PGE2 as a candidate (Fig. 5).
A hypotensive, natriuretic neutral lipid has been isolated
from dog renal medulla. This material, called medullipin,
is synthesized in the medulla and activated by passage
through the liver [35, 36]. Another anonymous neutral
lipid with chemical properties similar to CAF is gener-
ated by the renal tubular catabolism of albumin [37]. That
lipid is chemotaxic and stimulates renal adenylyl cyclase;
however, it does not co-localize with CAF by TLC. Thus
far, the molecular properties of all of these potent renal
bioactive lipids have eluded identification, largely due to
the vanishingly small quantities of the recovered com-
pounds that can be isolated.
The capacity of PKD cells to generate cAMP within
cyst cells in situ will also be determined by rate at which
the nucleotide is metabolized by phosphodiesterase. Re-
cent evidence indicates that inhibitors of this enzyme
increase the levels of cAMP in ADPKD cyst epithelial
cells [9]. Consequently, the use of phosphodiesterase in-
hibitors such as theophylline and caffeine may accentuate
the effects of common endogenous adenylyl cyclase ago-
nists and CAF.
The clinical relevance of the current studies depends
upon the extent to which cultured renal epithelial cells
reflect the function of the in situ precursor cells. It is
important to note in this regard that the stimulation of
transepithelial fluid secretion by cAMP agonists has been
demonstrated in intact renal cysts in situ and in in vitro
studies of cells cultured from cysts [2, 3, 17, 23, 38]. Exper-
iments utilizing rodent models of PKD have also shown
that renal and urine levels of cAMP are abnormally in-
creased [12, 13, 39]. In a rat model of ADPKD, activation
of ERK has been demonstrated in whole kidney extracts
by western blot and in individual cysts by immunocyto-
chemistry [40]. Activated ERK has also been detected in
the epithelial cells lining ADPKD cysts [41]. Thus, the
data from cell culture studies, though indirect, support a
role for cAMP in fluid secretion and cell proliferation in
PKD.
CONCLUSION
The experiments reported in this study support the
view that cAMP is an important determinant of the rate at
which individual cysts enlarge within polycystic kidneys.
Moreover, there is a rich array of adenylyl cyclase recep-
tors that may be activated by common and unexpected
agonists such as CAF.
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